Login to Your Account



Other News To Note


Friday, October 25, 2013

• Cubist Pharmaceuticals Inc., of Lexington, Mass., completed its acquisition of Optimer Pharmaceuticals Inc., of San Diego, for up-front cash of $551 million. Optimer common stock ceased trading on Nasdaq Oct. 23. Cubist said the acquisition will help it to accelerate its development of products for the acute care and hospital settings. (See BioWorld Today, July 31, 2013, and Aug. 1, 2013.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription